Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into the recent top-line data for VK2809 in treating NASH/NAFLD

Ticker(s): VKTX, MDGL

Who's the expert?

Name: Dr Vivek Kaul - MD

Institution: University of Rochester

  • Chief of the Division of Gastroenterology and Hepatology & Professor of Medicine at URMC.
  • 2 decades of experience performing colonoscopies; Treats 100+ patients with NAFLD and serves on several national committees with the ASGE and the ACG.
  • Clinical, research and medical education efforts are focused in Therapeutic Endoscopy, Interventional Endoscopic Ultrasound, advanced ERCP, esophageal endotherapy for Barrett's & Hepato-pancreatico-biliary disease.

Interview Goal
This call will focus on therapies currently in development to treat NASH and NAFLD with a focus on VK2809, a small molecule thyroid beta agonist in Phase 2 development for the treatment of NAFLD and hypercholesterolemia.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.